Medicare to Cover Crescendo Bio's RA Test | GenomeWeb

NEW YORK (GenomeWeb News) – Crescendo Bioscience today announced Medicare is covering its Vectra DA test for rheumatoid arthritis.

Medicare contractor Palmetto GBA has established national coverage for the South San Francisco, Calif. firm's test for assessing RA activity, in conjunction with standard clinical assessment, in adults who previously were diagnosed with the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.